Director Elizabeth Cermak filed a Form 4 with the SEC on November 19, 2026, disclosing the acquisition of stock options in Moleculin Biotech, Inc. (NASDAQ:MBRX) on November 17, 2026.

Key Highlights

  • Reporting person: Elizabeth Cermak, identified as a Director of Moleculin Biotech, Inc.
  • Transaction: Acquisition (Code A) of 4,000 stock options (right to buy) on November 17, 2026.
  • Exercise price: $6.83 per share, with an expiration date of November 17, 2036.
  • Vesting condition: Options vest on the earlier of November 17, 2027, or the date of the company's next annual meeting of shareholders, subject to continued Board service.
  • Post-transaction holdings: Cermak beneficially owns 4,331 derivative securities (stock options) following the reported transaction.
  • Purpose: According to the filing, the options were issued in connection with the reporting person's Board of Director service to the company.

Moleculin Biotech Director Elizabeth Cermak Receives Board Service Options in November 2026

According to the Form 4 filed on November 19, 2026, Elizabeth Cermak, a Director of Moleculin Biotech, Inc., acquired 4,000 stock options (right to buy common stock) on November 17, 2026. The filing identifies NASDAQ:MBRX as the issuer. The options carry an exercise price of $6.83 and are set to expire on November 17, 2036. The transaction was recorded under Code A, indicating an acquisition of derivative securities.

The filing states that the options vest on the earlier of November 17, 2027, or the date of the company's next annual meeting of shareholders, subject to the grantee's continued service on the company's Board of Directors on the vesting date. The filing further notes that the options were issued in connection with the reporting person's Board of Director service to the company.

Following the reported transaction, the filing discloses that Cermak beneficially owns 4,331 stock options in total, held directly. No non-derivative securities transactions were reported in Table I of the filing. The Form 4 was signed by Jonathan Foster by Power of Attorney and dated November 19, 2026.

What Was Disclosed

Moleculin Biotech Director Elizabeth Cermak disclosed the acquisition of 4,000 stock options at an exercise price of $6.83, expiring November 17, 2036, issued for Board service, with total post-transaction beneficial ownership of 4,331 options.